It has been proposed that boron neutron capture therapy (BNCT) holds promise as a treatment modality for melanoma. However, the effectiveness of boron agents in delivery remains a critical issue to be addressed for BNCT. To this end, phenylboronic acid, which exhibits good water solubility and low cytotoxicity similar to BPA, has been investigated as a potential nuclear-targeting boron agent. The boron concentration of phenylboronic acid was found to be 74.47 ± 12.17 ng/10⁶ B16F10 cells and 45.77 ± 5.64 ng/10⁶ cells in the nuclei. Molecular docking experiments were conducted to investigate the binding of phenylboronic acid to importin proteins involved in nuclear transport. The potential of phenylboronic acid to serve as a desirable nucleus-delivery boron agent for neutron capture therapy in melanoma warrants further exploration.

有人提出硼中子捕获疗法（BNCT）有望成为黑色素瘤的治疗方式。然而，硼剂输送的有效性仍然是 BNCT 需要解决的关键问题。为此，苯基硼酸具有良好的水溶性和与 BPA 相似的低细胞毒性，已被研究作为一种潜在的核靶向硼剂。发现苯硼酸的硼浓度在细胞核中为 74.47 ± 12.17 ng/10 ⁶ B16F10 细胞和 45.77 ± 5.64 ng/10 ⁶细胞。进行分子对接实验以研究苯硼酸与参与核运输的输入蛋白的结合。苯硼酸作为黑色素瘤中子捕获治疗理想的核输送硼剂的潜力值得进一步探索。